Drug Trial News

RSS
Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

6 Dec 2011
EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

5 Dec 2011
Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

5 Dec 2011
Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

5 Dec 2011
NanoViricides submits pre-IND Meeting Request for FluCide to FDA

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

5 Dec 2011
Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

5 Dec 2011
Zalicus commences Z160 Phase 1 clinical trial for pain

Zalicus commences Z160 Phase 1 clinical trial for pain

5 Dec 2011
Post-baseline vision data from Lundbeck's Sabril patient registry presented at AES meeting

Post-baseline vision data from Lundbeck's Sabril patient registry presented at AES meeting

5 Dec 2011
CDER, Shire enter agreement for ProAmatine clinical trial to treat symptomatic orthostatic hypotension

CDER, Shire enter agreement for ProAmatine clinical trial to treat symptomatic orthostatic hypotension

3 Dec 2011
Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease

Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease

3 Dec 2011
Progesterone can benefit women with catamenial seizures: Study

Progesterone can benefit women with catamenial seizures: Study

3 Dec 2011
Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

3 Dec 2011
Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV

Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV

3 Dec 2011
Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV

Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV

2 Dec 2011
John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

2 Dec 2011
Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

2 Dec 2011
Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

2 Dec 2011
AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

2 Dec 2011
ADVENTRX, FDA discuss ANX-188 development plans for treatment of sickle cell crisis

ADVENTRX, FDA discuss ANX-188 development plans for treatment of sickle cell crisis

1 Dec 2011
Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

1 Dec 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback